Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 21, 2016; 22(47): 10432-10439
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Table 2 Bivariant analysis with steroid-free remission according to Mayo score at week 14 of golimumab treatment n (%)
| Variable | NO SFR: n = 16 (48.5) | SFR: n = 17 (51.5) | P value |
| Age (yr) | 38.36 ± 13.6 | 46.35 ± 13.7 | NS |
| Mo since diagnosis | 72.20 ± 96.11 | 74.65 ± 67.65 | NS |
| Female sex | 10 (62.5) | 8 (47.1) | NS |
| Diagnosis < 2 yr | 7 (46.7) | 14 (82.4) | 0.03 |
| Anti-TNF naïve | 3 (18.8) | 6 (35.3) | NS |
| > 1 previous anti-TNF | 9 (56.3) | 7 (41.2) | NS |
| Steroid-dependent | 15 (93.8) | 9 (52.9) | 0.01 |
| Steroid-refractory | 4 (25.0) | 3 (17.6) | NS |
| mean ± SD | |||
- Citation: Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439
- URL: https://www.wjgnet.com/1007-9327/full/v22/i47/10432.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i47.10432